SGLT2 Inhibitors for Heart Failure and Type 2 Diabetes
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 30 (estimated)
- Sponsor
- The University of Texas Health Science Center at San Antonio · Other
This trial is looking for people with type 2 diabetes and certain heart issues to study the effects of SGLT2 inhibitors. Participants will be monitored for their heart function and physical abilities.
You may be able to join if
- I have been diagnosed with type 2 diabetes
- I have Class II-III heart failure
- I am between 18 and 80 years old
- My body mass index (BMI) is between 23 and 38
- My blood pressure is 145/85 mmHg or lower
- My blood sugar level (HbA1c) is between 5.5% and 10%
- My kidney function (eGFR) is 30 ml/min or better
- I have a stable weight for the last 3 months
You may not be able to join if
- I have been treated with an SGLT2 inhibitor or GLP-1 RA
- I am pregnant, breastfeeding, or planning to become pregnant
- I am allergic to the study drugs or their ingredients
- I have cancer
- I currently use drugs or alcohol
- I cannot give written consent
- I have severe claustrophobia
- I have a metal implant that makes MRI impossible
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Loading trial locations…